Disease Detail

ID DOID:4450
Name renal cell carcinoma
Definition A renal carcinoma that has_material_basis_in the lining of the proximal convoluted renal tubule of the kidney.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer urinary system cancer kidney cancer renal carcinoma renal cell carcinoma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Everolimus renal cell carcinoma not applicable detail...
Unknown unknown Famitinib renal cell carcinoma not applicable detail...
Unknown unknown Lenvatinib renal cell carcinoma not applicable detail...
Unknown unknown Pazopanib renal cell carcinoma not applicable detail...
VHL negative STF-62247 renal cell carcinoma sensitive detail...
Unknown unknown Tivozanib renal cell carcinoma not applicable detail...
Unknown unknown GDC-0349 renal cell carcinoma not applicable detail...
Unknown unknown Everolimus + Lenvatinib renal cell carcinoma not applicable detail...
Unknown unknown Sunitinib renal cell carcinoma not applicable detail...
Unknown unknown Alpha 2 Interferon + Bevacizumab renal cell carcinoma not applicable detail...
Unknown unknown Sorafenib renal cell carcinoma not applicable detail...
Unknown unknown Dovitinib renal cell carcinoma not applicable detail...
Unknown unknown Axitinib renal cell carcinoma not applicable detail...
CDKN2A loss Palbociclib renal cell carcinoma sensitive detail...
VHL mutant Sunitinib renal cell carcinoma predicted - sensitive detail...
VHL loss Bevacizumab renal cell carcinoma sensitive detail...
VHL loss ELR510444 renal cell carcinoma sensitive detail...
VHL mutant Everolimus renal cell carcinoma sensitive detail...
Unknown unknown Temsirolimus renal cell carcinoma not applicable detail...
Unknown unknown Tivantinib renal cell carcinoma not applicable detail...
Unknown unknown GW5074 + Sorafenib renal cell carcinoma not applicable detail...
Unknown unknown Bevacizumab + Temsirolimus renal cell carcinoma not applicable detail...
BRAF V600E Vemurafenib renal cell carcinoma predicted - sensitive detail...
Unknown unknown GDC-0980 renal cell carcinoma not applicable detail...
PTEN dec exp GDC-0980 renal cell carcinoma no benefit detail...
PIK3CA act mut PTEN dec exp GDC-0980 renal cell carcinoma no benefit detail...
VHL inact mut GDC-0980 renal cell carcinoma no benefit detail...
PTEN dec exp Everolimus renal cell carcinoma no benefit detail...
PIK3CA act mut PTEN dec exp Everolimus renal cell carcinoma no benefit detail...
VHL inact mut Everolimus renal cell carcinoma predicted - sensitive detail...
Unknown unknown GSK2126458 renal cell carcinoma not applicable detail...
Unknown unknown Cabozantinib renal cell carcinoma not applicable detail...
Unknown unknown AGS-003 + Sunitinib renal cell carcinoma not applicable detail...
Unknown unknown Nivolumab renal cell carcinoma not applicable detail...
FGFR1 over exp Sorafenib renal cell carcinoma not applicable detail...
VHL del Regorafenib renal cell carcinoma predicted - sensitive detail...
Unknown unknown AS1409 renal cell carcinoma not applicable detail...
Unknown unknown Bevacizumab + Everolimus renal cell carcinoma not applicable detail...
ARID1A mutant Bevacizumab + Everolimus renal cell carcinoma predicted - sensitive detail...
Unknown unknown 23814 renal cell carcinoma not applicable detail...
Unknown unknown Sunitinib + Trametinib renal cell carcinoma not applicable detail...
Unknown unknown Pazopanib + Trametinib renal cell carcinoma not applicable detail...
Unknown unknown sonepcizumab renal cell carcinoma not applicable detail...
VHL inact mut Alpha 2 Interferon + Bevacizumab renal cell carcinoma predicted - sensitive detail...
Unknown unknown Itraconazole renal cell carcinoma not applicable detail...
Unknown unknown Axitinib + Dalantercept renal cell carcinoma not applicable detail...
Unknown unknown CB-839 + Everolimus renal cell carcinoma not applicable detail...
Unknown unknown Abexinostat + Pazopanib renal cell carcinoma not applicable detail...
Unknown unknown MK2206 renal cell carcinoma no benefit detail...
VHL loss BPTES renal cell carcinoma sensitive detail...
VHL loss CB-839 renal cell carcinoma sensitive detail...
VHL loss CB-839 + Olaparib renal cell carcinoma sensitive detail...
VHL loss BPTES + Olaparib renal cell carcinoma sensitive detail...
Unknown unknown CPI-444 renal cell carcinoma not applicable detail...
Unknown unknown Atezolizumab + CPI-444 renal cell carcinoma not applicable detail...
Unknown unknown Everolimus + Sunitinib renal cell carcinoma not applicable detail...
Unknown unknown Ipilimumab + Nivolumab renal cell carcinoma not applicable detail...
Unknown unknown Gemcitabine + MU380 renal cell carcinoma not applicable detail...
Unknown unknown Bevacizumab + Carotuximab renal cell carcinoma no benefit detail...
Unknown unknown Pazopanib + Pembrolizumab renal cell carcinoma no benefit detail...
VHL mutant N/A renal cell carcinoma no benefit detail...
Unknown unknown Pegilodecakin renal cell carcinoma not applicable detail...
Unknown unknown Everolimus + Vorolanib renal cell carcinoma not applicable detail...
Unknown unknown Axitinib + X4P-001 renal cell carcinoma not applicable detail...
PTEN loss Everolimus renal cell carcinoma predicted - sensitive detail...
Unknown unknown Axitinib + Carotuximab renal cell carcinoma not applicable detail...
Unknown unknown Avelumab + Axitinib renal cell carcinoma not applicable detail...
Unknown unknown ODM-203 renal cell carcinoma not applicable detail...
Unknown unknown AGS16F renal cell carcinoma not applicable detail...
Unknown unknown Axitinib + Pembrolizumab renal cell carcinoma not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00003553 Phase II Cyclophosphamide + Fludarabine Cyclosporine Mycophenolate mofetil Methotrexate Peripheral Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer Unknown status
NCT00301990 Phase II Aldesleukin + Bevacizumab Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer Unknown status
NCT00717587 Phase II Sunitinib Girentuximab motexafin gadolinium Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer Unknown status
NCT00828919 Phase I Axitinib Continuing Access To AG- 013736 (A406) For Patients Previously Receiving AG 013736 In Clinical Trials Active, not recruiting
NCT00923130 Phase II Bevacizumab + Ixabepilone Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer Completed
NCT00923845 Phase II Sirolimus Cyclophosphamide + Pentostatin Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer Completed
NCT01014065 Phase II Sunitinib A Prospective Study of Acute Cardiovascular Effects of First-line Sunitinib in Metastatic Renal Cell Carcinoma Patients (SUnitinib Prospective CardiovasculaR Effect) Completed
NCT01026337 Phase 0 Sunitinib Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer Completed
NCT01120249 Phase III Everolimus S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Active, not recruiting
NCT01164228 Phase II Sunitinib Gemcitabine Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery Active, not recruiting
NCT01221506 Phase I Pazopanib Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC) Completed
NCT01283048 Phase I Bevacizumab + Buparlisib Bevacizumab and BKM-120 in Patients With Metastatic Renal Cell Carcinoma Completed
NCT01307267 Phase I Rituximab + Utomilumab Utomilumab A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab Completed
NCT01331135 Phase I Sirolimus Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors Active, not recruiting
NCT01361113 Phase II Pazopanib Neoadjuvant Pazopanib in Renal Cell Carcinoma Completed
NCT01370109 Phase I Sunitinib Cardiovascular Effects of Sunitinib Therapy (CREST) Completed
NCT01391143 Phase I MGA271 Safety Study of MGA271 in Refractory Cancer Active, not recruiting
NCT01399918 Phase II Bevacizumab + Everolimus Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC) Active, not recruiting
NCT01480154 Phase I Hydroxychloroquine + MK2206 Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer Active, not recruiting
NCT01510119 Phase Ib/II Everolimus + Hydroxychloroquine Autophagy Inhibition to Augment mTOR Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine in Patients With Previously Treated Renal Cell Carcinoma Completed
NCT01517243 Phase II Temsirolimus Sunitinib Phase II Study of Alternating Sunitinib and Temsirolimus Active, not recruiting
NCT01575548 Phase III Pazopanib Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery Active, not recruiting
NCT01582009 Phase Ib/II Everolimus + Panobinostat Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate Terminated
NCT01582672 Phase III Sunitinib Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC) Terminated
NCT01625936 Phase I Bevacizumab CRLX101 CRLX101 Plus Bevacizumab in Advanced RCC Completed
NCT01649180 Phase II Axitinib NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma (PrE0801) Terminated
NCT01664182 Phase II Sunitinib + Trebananib Pazopanib + Trebananib Sorafenib + Trebananib Trebananib Bevacizumab + Trebananib Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer Active, not recruiting
NCT01727336 Phase II Axitinib + Dalantercept Axitinib Study of Dalantercept in Patients With Advanced Renal Cell Carcinoma Completed
NCT01730118 Phase I HER2 Vaccine Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing Recruiting
NCT01767636 Phase II Pazopanib Pazopanib in Treating Patients With Metastatic Non-Clear Cell Kidney Cancer Active, not recruiting
NCT01806064 Phase I Bevacizumab + Carotuximab A Phase 1B Dose-escalation Study of TRC105 in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma Active, not recruiting
NCT01835158 Phase II Cabozantinib Cabozantinib + Sunitinib Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer Active, not recruiting
NCT01865747 Phase III Everolimus Cabozantinib A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma Active, not recruiting
NCT01946789 Phase I ALT-803 A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors Completed
NCT01984242 Phase II Atezolizumab Sunitinib Atezolizumab + Bevacizumab + Capecitabine A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) as Monotherapy or in Combination With Avastin (Bevacizumab) Compared to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma Completed
NCT02009449 Phase I Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Carboplatin Gemcitabine Docetaxel Pazopanib Capecitabine Paclitaxel Cisplatin Pegilodecakin Nab-paclitaxel A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors Active, not recruiting
NCT02013804 Phase I MEDI0680 A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies Completed
NCT02014636 Phase I Pazopanib Pembrolizumab Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC) Completed
NCT02071862 Phase I CB-839 + Everolimus CB-839 + Erlotinib CB-839 + Docetaxel CB-839 CB-839 + Paclitaxel Cabozantinib + CB-839 Study of the Glutaminase Inhibitor CB-839 in Solid Tumors Active, not recruiting
NCT02082210 Phase Ib/II Emibetuzumab + Ramucirumab A Study of LY2875358 in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer Completed
NCT02089334 Phase Ib/II Everolimus + RX-0201 Everolimus Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer Terminated
NCT02089685 Phase Ib/II Ipilimumab peginterferon alfa-2b Pembrolizumab Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29) Active, not recruiting
NCT02122809 Phase I Chiauranib Phase I Study of Chiauranib in Patients With Advanced Solid Tumors Completed
NCT02133742 Phase I Axitinib + Pembrolizumab A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer Active, not recruiting
NCT02164838 Phase I Axitinib VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors Completed
NCT02170389 Phase I AGS-003 Vaccine Therapy Before Surgery in Treating Patients With Localized Kidney Cancer Terminated
NCT02174172 Phase I Atezolizumab + Bevacizumab + Peg-interferon alfa-2a Atezolizumab + Interferon alpha-2b Atezolizumab + Peg-interferon alfa-2a Atezolizumab + Ipilimumab Atezolizumab + Obinutuzumab A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors Active, not recruiting
NCT02178722 Phase Ib/II Epacadostat + Pembrolizumab A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (INCB 24360-202 / MK-3475-037 / KEYNOTE-037/ ECHO-202) Active, not recruiting
NCT02187302 Phase II Bevacizumab + CRLX101 CRLX101 in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC) Completed
NCT02212730 Phase I Pembrolizumab A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell Cancer (MK-3475-031) Active, not recruiting
NCT02231749 Phase III Ipilimumab + Nivolumab Sunitinib Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) Active, not recruiting
NCT02273752 Phase II Everolimus Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer Terminated
NCT02298959 Phase I Aflibercept + Pembrolizumab Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors Recruiting
NCT02404441 Phase Ib/II Spartalizumab Phase I/II Study of PDR001 in Patients With Advanced Malignancies Active, not recruiting
NCT02406521 Phase I Pazopanib Radium Ra 223 dichloride Sorafenib Exploratory Study of Radium-223 and Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Metastases Active, not recruiting
NCT02420821 Phase III Bevacizumab Sunitinib Atezolizumab A Study of MPDL3280A (Anti-Programmed Death Ligand 1 [PD-L1] Antibody) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma Active, not recruiting
NCT02432846 Phase II Sunitinib Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC) (MERECA) Active, not recruiting
NCT02432963 Phase I MVAp53 + Pembrolizumab Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy Active, not recruiting
NCT02471846 Phase I GDC-0919 Atezolizumab A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors Active, not recruiting
NCT02493751 Phase I Avelumab + Axitinib A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer Active, not recruiting
NCT02495103 Phase Ib/II Metformin + Vandetanib Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma Recruiting
NCT02498665 Phase I DSP-7888 A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies Active, not recruiting
NCT02501096 Phase Ib/II Pembrolizumab Lenvatinib Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors Recruiting
NCT02543645 Phase Ib/II Atezolizumab + Varlilumab A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer Terminated
NCT02559492 Phase I Epacadostat + Itacitinib Itacitinib + Parsaclisib INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors Active, not recruiting
NCT02560012 Phase II Everolimus Sorafenib Temsirolimus Axitinib Sunitinib Pazopanib Personalized Targeted Inhibitors Treatment in Renal Cell Cancer Terminated
NCT02576665 Phase I Toca 511 + Toca FC A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors (Toca6) Active, not recruiting
NCT02596035 FDA approved Nivolumab A Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374) Active, not recruiting
NCT02599779 Phase II Pembrolizumab A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients Recruiting
NCT02608268 Phase Ib/II Spartalizumab MBG453 Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies Recruiting
NCT02608385 Phase I Pembrolizumab Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors Recruiting
NCT02619253 Phase Ib/II Pembrolizumab + Vorinostat Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma Recruiting
NCT02627963 Phase III Sorafenib Tivozanib A Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC Active, not recruiting
NCT02639182 Phase II AGS16F Axitinib A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma Active, not recruiting
NCT02646319 Phase I Nab-Rapamycin Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations Completed
NCT02646748 Phase I Itacitinib + Pembrolizumab Parsaclisib + Pembrolizumab Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors Active, not recruiting
NCT02650635 Phase I Cyclophosphamide + Motolimod + Pegfilgrastim TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors Terminated
NCT02655822 Phase I Atezolizumab + CPI-444 CPI-444 Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers Recruiting
NCT02684006 Phase III Avelumab + Axitinib Sunitinib A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101) Active, not recruiting
NCT02697591 Phase Ib/II INCAGN01876 An Open-Label, Dose-Escalation, Safety Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors Active, not recruiting
NCT02718066 Phase Ib/II Chidamide + Nivolumab Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer Recruiting
NCT02721732 Phase II Pembrolizumab Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors Recruiting
NCT02724020 Phase II MLN1117 + Sapanisertib Sapanisertib Everolimus MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Active, not recruiting
NCT02724878 Phase II Atezolizumab + Bevacizumab + Capecitabine Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Active, not recruiting
NCT02729194 Phase I Pazopanib Pilot Study of Pazopanib With Low Fat Meal (PALM) in Advanced Renal Cell Carcinoma Completed
NCT02762006 Phase I Durvalumab + Tremelimumab Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma Recruiting
NCT02781506 Phase II Nivolumab Nivolumab and Stereotactic Ablative Radiation Therapy Versus Nivolumab Alone for Metastatic Renal Cancer Recruiting
NCT02795819 Phase I AR-42 + Pazopanib Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer Terminated
NCT02799095 Phase I ALKS 4230 A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors Recruiting
NCT02811861 Phase III Everolimus + Lenvatinib Sunitinib Lenvatinib + Pembrolizumab Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma Recruiting
NCT02835833 Phase I Bevacizumab + Nintedanib Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors Completed
NCT02853331 Phase III Axitinib + Pembrolizumab Sunitinib Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426) Active, not recruiting
NCT02853344 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427) Active, not recruiting
NCT02867592 Phase II Cabozantinib Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Recruiting
NCT02915783 Phase II Everolimus + Lenvatinib A Phase 2 Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease Active, not recruiting
NCT02922764 Phase I RGX-104 Nivolumab + RGX-104 A Study of RGX-104 With or Without Nivolumab in Patients With Advanced Solid Malignancies and Lymphoma Recruiting
NCT02923349 Phase Ib/II INCAGN01949 A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors Completed
NCT02923531 Phase Ib/II Nivolumab + X4P-001 Addition of X4P-001 to Nivolumab Treatment in Patients With Renal Cell Carcinoma Completed
NCT02950766 Phase I Ipilimumab + NeoVax A Study Combining NeoVax, a Personalized NeoAntigen Cancer Vaccine, With Ipilimumab to Treat High-risk Renal Cell Carcinoma Recruiting
NCT02952248 Phase I BI 754091 A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours Recruiting
NCT02956798 Phase II Pazopanib Pazopanib Vs. Local Therapy for Renal Cancer With Metastases Recruiting
NCT02962804 Phase II Nivolumab Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC) Withdrawn
NCT02982954 Phase III Ipilimumab + Nivolumab A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer (CHECKMATE 920) Active, not recruiting
NCT02983045 Phase Ib/II Nivolumab + NKTR-214 A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors (PIVOT-02) Recruiting
NCT02996110 Phase II Nivolumab + Relatlimab Ipilimumab + Nivolumab A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma (FRACTION-RCC) Recruiting
NCT03015740 Phase Ib/II MGCD516 + Nivolumab MGCD516 Combined With Nivolumab in Renal Cell Cancer (RCC) Recruiting
NCT03024437 Phase Ib/II Atezolizumab + Entinostat Atezolizumab + Bevacizumab + Entinostat Atezolizumab Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma Recruiting
NCT03024996 Phase III Atezolizumab A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy (IMmotion010) Active, not recruiting
NCT03029780 Phase II Ipilimumab + Nivolumab An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma Active, not recruiting
NCT03055013 Phase III Nivolumab Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy (PROSPER) Recruiting
NCT03063762 Phase I Atezolizumab + Obinutuzumab + RO6874281 Atezolizumab + Bevacizumab + Obinutuzumab + RO6874281 Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC) Active, not recruiting
NCT03065179 Phase II Ipilimumab + Nivolumab Trial of SBRT in Combination With Nivolumab/Ipilimumab in RCC / Kidney Cancer Patients Recruiting
NCT03092856 Phase II Axitinib Axitinib + PF-04518600 Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer Recruiting
NCT03097328 Phase II Sapanisertib Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma Recruiting
NCT03109015 Phase II Sunitinib Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing (ASSET) Recruiting
NCT03111901 Phase Ib/II Aldesleukin + Pembrolizumab Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer Withdrawn
NCT03115801 Phase II Atezolizumab Nivolumab A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers Recruiting
NCT03117309 Phase II Ipilimumab + Nivolumab Nivolumab Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma Recruiting
NCT03126331 Phase II Nivolumab Intermittent Nivolumab in Metastatic Renal Cell Carcinoma Patients Recruiting
NCT03138512 Phase III Ipilimumab + Nivolumab A Study Comparing the Combination of Nivolumab and Ipilimumab Versus Placebo in Participants With Localized Renal Cell Carcinoma (CheckMate 914) Recruiting
NCT03141177 Phase III Cabozantinib + Ipilimumab + Nivolumab Sunitinib Cabozantinib + Nivolumab A Study of Nivolumab Combined With Cabozantinib or Nivolumab and Ipilimumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 9ER) Active, not recruiting
NCT03142334 Phase III Pembrolizumab Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564) Recruiting
NCT03149822 Phase Ib/II Cabozantinib + Pembrolizumab Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma Recruiting
NCT03163667 Phase II CB-839 + Everolimus Everolimus CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC Active, not recruiting
NCT03165721 Phase II Guadecitabine A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer Recruiting
NCT03172754 Phase Ib/II Axitinib + Nivolumab Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma Recruiting
NCT03175224 Phase I CBT-101 CBT-101 Study for Advanced Solid Tumors and c-Met Dysregulation Recruiting
NCT03189186 Phase I Pembrolizumab Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas Withdrawn
NCT03200587 Phase I Avelumab + Cabozantinib Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC) Recruiting
NCT03203473 Phase II Nivolumab Ipilimumab + Nivolumab Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study) Recruiting
NCT03207347 Phase II Niraparib A Trial of Niraparib in BAP1 and Other DNA Double-Strand Break Repair Deficient Neoplasms (UF-STO-ETI-001) Recruiting
NCT03207867 Phase II PBF-509 + Spartalizumab A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma Recruiting
NCT03239145 Phase I Pembrolizumab + Trebananib Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor Recruiting
NCT03241173 Phase Ib/II INCAGN01949 + Ipilimumab INCAGN01949 + Nivolumab INCAGN01949 + Ipilimumab + Nivolumab A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies Active, not recruiting
NCT03260504 Phase I Aldesleukin + Pembrolizumab Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer Recruiting
NCT03260894 Phase III Epacadostat + Pembrolizumab Pazopanib + Sunitinib Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC Active, not recruiting
NCT03264066 Phase II Atezolizumab + Cabozantinib A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors Recruiting
NCT03277352 Phase Ib/II Epacadostat + INCAGN01876 + Pembrolizumab INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies Active, not recruiting
NCT03289962 Phase I RO7198457 Atezolizumab + RO7198457 A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors Recruiting
NCT03311334 Phase I Atezolizumab + DSP-7888 DSP-7888 + Nivolumab A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Subjects With Advanced Solid Tumors Recruiting
NCT03319459 Phase I FATE-NK100 FATE-NK100 + Trastuzumab Cetuximab + FATE-NK100 FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors Recruiting
NCT03324373 Phase II Everolimus + Lenvatinib Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC) Recruiting
NCT03329950 Phase I CDX-1140 + CDX-301 CDX-1140 A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors Recruiting
NCT03396211 Phase I Apatinib + Nivolumab Study to Evaluate Apatinib Plus Nivolumab in Patients With Unresectable or Metastatic Cancer Recruiting
NCT03401788 Phase II PT 2977 A Phase 2 Study of PT2977 for the Treatment of Von Hippel Lindau Disease-Associated Renal Cell Carcinoma Active, not recruiting
NCT03428217 Phase II Cabozantinib Cabozantinib + CB-839 CB-839 With Cabozantinib vs. Placebo With Cabozantinib in Patients With Metastatic Renal Cell Carcinoma (CANTATA) Recruiting
NCT03435640 Phase Ib/II NKTR-214 + NKTR-262 Nivolumab + NKTR-214 + NKTR-262 A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies Recruiting
NCT03454451 Phase I CPI-006 CPI-006 + Pembrolizumab CPI-006 + CPI-444 CPI-006 Alone and in Combination With CPI-444 and With Pembrolizumab for Patients With Advanced Cancers Recruiting
NCT03473730 Phase I Daratumumab Daratumumab in Patients With Metastatic Renal Cell Carcinoma (MRCC) or Muscle Invasive Bladder Cancer Recruiting
NCT03474497 Phase Ib/II Aldesleukin + Pembrolizumab + Radiotherapy Intralesional IL-2, Hypofractionated Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade Recruiting
NCT03501381 Phase II Entinostat + Interleukin-12 Interleukin-12 High Dose IL 2 and Entinostat in RCC Recruiting
NCT03502330 Phase I APX005M + Cabiralizumab + Nivolumab APX005M + Cabiralizumab APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma Recruiting
NCT03517488 Phase I XmAb20717 A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) Recruiting
NCT03525795 Phase Ib/II CPI-1205 + Ipilimumab ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors Active, not recruiting
NCT03538028 Phase I INCAGN02385 A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies Recruiting
NCT03541902 Phase II Cabozantinib Sunitinib Cabozantinib Versus Sunitinib for Metastatic Variant Histology Renal Cell Carcinoma Recruiting
NCT03552380 Phase II Entinostat + Ipilimumab + Nivolumab Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma Recruiting
NCT03562507 Phase II CEP-11981 CEP-11981 + Nivolumab Phase 2 Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma Recruiting
NCT03592472 Phase III Pazopanib Abexinostat + Pazopanib A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV) Active, not recruiting
NCT03595124 Phase II Nivolumab Axitinib + Nivolumab Axitinib Axitinib and Nivolumab in Treating Participants With Unresectable or Metastatic TFE/Translocation Renal Cell Carcinoma Recruiting
NCT03598816 Phase II Durvalumab + Tremelimumab PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma Not yet recruiting
NCT03608020 Phase Ib/II BMX-001 A Trial for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy Recruiting
NCT03621982 Phase I Camidanlumab Tesirine Study of ADCT-301 in Patients With Selected Advanced Solid Tumors Recruiting
NCT03628677 Phase I AB154 AB154 + GLS-010 A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies Recruiting
NCT03629756 Phase I AB928 + GLS-010 A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies Recruiting
NCT03633110 Phase Ib/II GEN-009 GEN-009 + Nivolumab Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine Recruiting
NCT03634540 Phase II Cabozantinib + PT 2977 A Trial of PT2977 in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) Recruiting
NCT03635892 Phase II Cabozantinib + Nivolumab A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma Recruiting
NCT03637803 Phase I MRx0518 + Pembrolizumab MRx0518 and Pembrolizumab Combination Study Recruiting
NCT03656718 Phase Ib/II Nivolumab + rHuPH20 A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20) Recruiting
NCT03679767 Phase II INCMGA00012 A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) Recruiting
NCT03729245 Phase III Cabozantinib + Sunitinib Nivolumab + NKTR-214 A Study of NKTR-214 in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC) Recruiting
NCT03758781 Phase I Cyclophosphamide + IRX-2 + Nivolumab IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors Recruiting
NCT03775850 Phase Ib/II EDP1503 EDP1503 + Pembrolizumab A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors Recruiting
NCT03786796 Phase II Olaparib Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations (ORCHID) Recruiting
NCT03793166 Phase III Nivolumab Cabozantinib + Nivolumab Cabozantinib Ipilimumab + Nivolumab Nivolumab and Ipilimumab Followed by Nivolumab Versus Cabozantinib and Nivolumab in Treating Patients With Metastatic Untreated Renal Cell Cancer Recruiting
NCT03816345 Phase I Nivolumab Nivolumab in Treating Patients With Autoimmune Disorders or Advanced, Metastatic, or Unresectable Cancer Recruiting
NCT03845166 Phase I XL092 A Study of XL092 in Subjects With Solid Tumors Recruiting
NCT03849469 Phase I Pembrolizumab + XmAb22841 XmAb22841 A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4) Recruiting
NCT03873402 Phase III Nivolumab Ipilimumab + Nivolumab An Immunotherapy Study of Nivolumab Plus Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer Recruiting
NCT03889782 Phase II Aldesleukin + Nivolumab High Dose IL-2 in Combination With Anti-PD-1 in Metastatic Melanoma and Renal Cell Carcinoma Not yet recruiting
NCT03905889 Phase I Abemaciclib + Sunitinib A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma Recruiting
NCT03977467 Phase II Atezolizumab + Carboplatin Atezolizumab + Cisplatin Atezolizumab Atezolizumab + Bevacizumab + Carboplatin Atezolizumab + Bevacizumab + Cisplatin Atezolizumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor Not yet recruiting
NCT03991130 Phase II Aldesleukin + Nivolumab High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma Recruiting